Ver­tex is pulling back on its ge­net­ic med­i­cine re­search, end­ing all work re­lat­ed to ade­no-as­so­ci­at­ed virus­es, ...

The White House’s budget request proposes a nearly $18 billion cut to NIH spending, and nearly $4 billion slashed at the CDC.

Aera Therapeutics shifts focus to lipid nanoparticles for T-cell targeting therapy while continuing work on protein ...

Welcome back to Endpoints Weekly, our roundup of the top headlines in biopharma. Earnings season continued this week, with more comments from pharma executives on the potential impact of tariffs ...

Kura gets $45M from Kyowa Kirin; Pliant cuts 45% staff; AstraZeneca's Breztri succeeds in asthma trials; Otsuka ends ...

SalioGen Therapeutics, led by Ray Tabibiazar, shut down after failing to perfect its bat-derived gene editing technology.

Pathos AI, a Chicago biotech led by executives of the healthcare AI group Tempus, is looking at a funding round of up to $400 ...

Aviva Capital Partners & Socius plan £1B cancer research hub in Sutton, UK, near Institute of Cancer Research & Royal Marsden ...

FDA delays Cytokinetics' aficamten PDUFA date to Dec 26 after company adds REMS to heart disease drug application; stock down ...

When Siren Biotechnology CEO Nicole Paulk learned last month that top FDA official Peter Marks had resigned, she began ...

Regeneron can’t dodge a lawsuit alleging it unlawfully inflated Medicare reimbursements for its eye drug Eylea and defrauded ...

Amicus pays Dimerix $30M upfront for US rights to DMX-200, a late-stage FSGS therapy, with potential milestone payments of ...